EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Effectiveness, Safety and Pharmacokinetics of BGM0504 , a Dual GLP ‐1/ GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double‐Blind, Placebo‐Controlled Trial

Linong Ji iD, Guoping Yang iD, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Zou Chan, Haibin Zhang, Jiandong Yuan

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11463-11474

DOI: 10.1111/dom.71193 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.09.2026. Verfasst von Linong Ji und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Obesity, Overweight, Glucagon-Like Peptide-1 Receptor Agonists, Receptors, Gastrointestinal Hormone. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of the dual GLP‐1R/GIPR agonist BGM0504 in Chinese adults with overweight or obesity without diabetes. Materials and Methods In this randomized, double‐blind, placebo‐controlled, parallel‐group phase 2 trial, 120 participants were assigned (1:1:1:1) to receive once‐weekly subcutaneous injections of BGM0504 5 mg, 10 mg, 15 mg, or placebo for 24 weeks. The primary endpoint was percentage change in body weight from baseline to week 24. Key secondary endpoints included absolute body weight change, waist circumference, and the proportions of participants achieving prespecified weight‐loss targets. Safety was assessed using adverse events, laboratory tests, and vital signs. The trial was registered with the Chinese National Medical Products Administration (CTR20233198) and ClinicalTrials.gov (NCT06973681).

Results

Mean percentage changes in body weight from baseline to week 24 were −10.68%, −16.07%, −18.33%, and 0.13% with BGM0504 5 mg, 10 mg, 15 mg, and placebo, respectively; all BGM0504 doses were significantly superior to placebo (all p < 0.0001). Mean reductions in waist circumference were −8.88 cm, −12.71 cm, −14.38 cm, and −1.03 cm, respectively (all p < 0.001 vs. placebo). The proportions of participants achieving clinically meaningful weight loss increased in a dose‐dependent manner across BGM0504 groups versus placebo (all p < 0.001). PK analyses showed an approximately linear dose‐exposure relationship across the evaluated dose range. TEAEs occurred in 96.7%, 93.5%, 100.0%, and 86.7% of participants in the BGM0504 5 mg, 10 mg, 15 mg, and placebo groups, respectively, and drug‐related adverse events occurred in 53.3%, 80.6%, 93.1%, and 40.0%. The most common selected TEAEs were gastrointestinal, including nausea, diarrhoea, and vomiting. One serious adverse event occurred in the 10 mg group and no TEAEs led to trial withdrawal.

Conclusions

Once‐weekly BGM0504 was associated with substantial dose‐dependent weight loss and acceptable tolerability in Chinese adults with overweight or obesity without diabetes, supporting further clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityOverweightGlucagon-Like Peptide-1 Receptor AgonistsReceptors, Gastrointestinal HormoneHypoglycemic AgentsAnti-Obesity AgentsHumansDouble-Blind MethodFemaleMaleAdultMiddle AgedWeight LossChinaTreatment OutcomeInjections, SubcutaneousDose-Response Relationship, DrugGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

BGM0504GIP receptorGLP‐1 receptorobesitypharmacokineticsphase 2 trial

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsReceptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorHypoglycemic AgentsAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
  • Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
  • BrightGene Bio-Medical Technology Co. Ltd., Suzhou, China.
  • The Sweetwood Group LLC, Rockville, Maryland, USA.
  • Beijing Noahpharm Medical Technology Co. Ltd., Beijing, China.

ORCID-Profile: Linong Ji, Guoping Yang

Zitieren

APA

Ji, L., Yang, G., Huang, Y., Ding, H., Xie, D., Jiang, X., Yuan, X., Cao, Z., Chan, Z., Zhang, H., & Yuan, J. (2026). Effectiveness, Safety and Pharmacokinetics of BGM0504 , a Dual GLP ‐1/ GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double‐Blind, Placebo‐Controlled Trial. Diabetes, Obesity and Metabolism, 28(12), 11463-11474. https://doi.org/10.1111/dom.71193

Vancouver

Ji L, Yang G, Huang Y, Ding H, Xie D, Jiang X, et al. Effectiveness, Safety and Pharmacokinetics of BGM0504 , a Dual GLP ‐1/ GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double‐Blind, Placebo‐Controlled Trial. Diabetes, Obesity and Metabolism. 2026;28(12):11463-11474. doi:10.1111/dom.71193

BibTeX
@article{Ji2026,
  author = {Ji, Linong and Yang, Guoping and Huang, Yangqing and Ding, Haifeng and Xie, Daosheng and Jiang, Xiaohui and Yuan, Xuemei and Cao, Zhao and Chan, Zou and Zhang, Haibin and Yuan, Jiandong},
  title = {Effectiveness, Safety and Pharmacokinetics of BGM0504 , a Dual GLP ‐1/ GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double‐Blind, Placebo‐Controlled Trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11463--11474},
  doi = {10.1111/dom.71193}
}
Kostenlos starten →